Conclusions

| Home | | Pharmacovigilance |

Chapter: Pharmacovigilance: The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Children and Adolescents

This review aimed to address the pressing clinical question of whether SSRI use for the treatment of depression differs in youth than in adults.


CONCLUSIONS

This review aimed to address the pressing clinical question of whether SSRI use for the treatment of depression differs in youth than in adults. Both efficacy and safety data raise serious concerns that youth outcomes are different, particularly in children. Data have been presented and their findings have been critiqued. Suggestions for further research are posed. Many publicized interpretations of the existing stud-ies suggest that the glass is ‘half full’ when the major long-term concern for use of SSRIs to treat depression in youth warrants a ‘half empty’ interpre-tation. Regardless of the clinical readers’ perspective, wisdom and FDA warnings demand caution and close monitoring.

Contact Us, Privacy Policy, Terms and Compliant, DMCA Policy and Compliant

TH 2019 - 2022 pharmacy180.com; Developed by Therithal info.